These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31027063)

  • 1. Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report.
    Ciurleo R; Sessa E; Marino S; D'Aleo G; Bramanti P; Rifici C
    Medicine (Baltimore); 2019 Apr; 98(17):e15185. PubMed ID: 31027063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
    Valencia-Sanchez C; Carter JL
    Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.
    Lorefice L; Fenu G; Cabras F; Frau J; Coghe GC; Loi L; Marrosu MG; Cocco E
    Mult Scler Relat Disord; 2016 May; 7():65-7. PubMed ID: 27237760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
    Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
    Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    Calabrese M; Pitteri M; Farina G; Bajrami A; Castellaro M; Magliozzi R; Monaco S
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1073-1078. PubMed ID: 28844068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
    Mallucci G; Annovazzi P; Miante S; Torri-Clerici V; Matta M; La Gioia S; Cavarretta R; Mantero V; Costantini G; D'Ambrosio V; Zaffaroni M; Ghezzi A; Perini P; Rossi S; Bertolotto A; Rottoli MR; Rovaris M; Balgera R; Cavalla P; Montomoli C; Bergamaschi R
    J Neurol; 2018 Aug; 265(8):1850-1859. PubMed ID: 29948245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis].
    de Sá J; Ferreira J; Macedo AM
    Rev Neurol; 2023 Jan; 76(s01):S1-S6. PubMed ID: 36683265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
    Mirabella M; Prosperini L; Lucchini M; Boffa L; Borriello G; Buscarinu MC; Centonze D; Cortese A; De Fino C; De Giglio L; Elia G; Fantozzi R; Ferraro E; Francia A; Galgani S; Gasperini C; Haggiag S; Landi D; Marfia GA; Millefiorini E; Monteleone F; Nociti V; Salvetti M; Sgarlata E; Pozzilli C
    CNS Drugs; 2018 Oct; 32(10):963-970. PubMed ID: 30022464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Mokliatchouk O; Jiang X; Lyons J; Kapadia S; Miller C
    Mult Scler; 2022 Apr; 28(5):801-816. PubMed ID: 34465252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Harmel P; Schlunk F; Harms L
    Mult Scler; 2018 Jul; 24(8):1131-1133. PubMed ID: 29708444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl fumarate in a patient with multiple sclerosis and type 1 diabetes mellitus: The importance of ketonuria.
    Krzystanek E; Jarosz-Chobot P
    Mult Scler Relat Disord; 2018 Apr; 21():42-45. PubMed ID: 29455073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis Portuguese Population.
    Barros A; Sequeira J; de Sousa A; Parra J; Brum M; Pedrosa R; Capela C
    Clin Neuropharmacol; 2020; 43(3):55-60. PubMed ID: 32384308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethyl fumarate-associated transient bone marrow oedema syndrome.
    Triplett J; Vijayan S; Prince R; Kermode A
    Mult Scler; 2019 May; 25(6):876-879. PubMed ID: 30051766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E; Sejbaek T
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.